



**For Immediate Release**

**VENTRIPOINT AND HOSPITAL FOR SICK CHILDREN ENTER INTO A MOU FOR  
INSTALLATION OF VENTRIPOINT MEDICAL SYSTEM**

**First Installation of the Commercial VentriPoint Medical System**

**SEATTLE, January 13, 2010** – VentriPoint Diagnostics Ltd. ("**VentriPoint**" or the "**Corporation**") (TSX Venture: **VPT**), and **Toronto's Hospital for Sick Children** (SickKids) have signed a *Memorandum of Understanding* (MOU) for the installation of the first commercial VENTRIPOINT MEDICAL SYSTEM (VMS) into the Echocardiography lab at the Labatt Family Heart Centre for use in monitoring children with congenital heart disease.

The VENTRIPOINT MEDICAL SYSTEM (VMS) generates critical heart measurements with significantly greater speed and accuracy and at a considerably lesser cost than is currently possible. The VMS generates those measurements from the two-dimensional ultrasound systems that are used widely in hospitals and clinics throughout the world. Health Canada and Europe have granted license approval for this breakthrough diagnostic tool, and VentriPoint anticipates responding to the U.S. Federal Drug Administration's 510(k) review requests for additional information before the end of January.

"As Canada's most research-intensive hospital and the third-largest hospital in the world for the care of children with congenital heart disease, SickKids represents an ideal hospital setting for the first commercial installation of a VentriPoint Medial System to monitor patients with congenital heart disease. We are honored to have the opportunity to collaborate with such an esteemed institution as SickKids and we look forward to working closely with their highly regarded professionals as we proceed to a definitive agreement and a mutually rewarding relationship," said Joseph Ashley, CEO of VentriPoint. This is an important step towards providing VMS's critical heart measurements to medical professionals around the world. In addition, VentriPoint has received strong interest from major cardiac centers in Canada, Europe and the United States.

"I developed this technology to improve the care of children and adults with congenital heart disease," added Dr. Sheehan, principal inventor of the VMS and Co-founder and Chief Scientist of VentriPoint, Inc. "Dr. Andrew Redington, Chief of Cardiology at SickKids, has called an easily applicable, real-time, three dimensional right ventricular volume assessment the "Holy Grail" of cardiographic assessment, and I am delighted that he will be the first to evaluate the VentriPoint Medical System."

**About VentriPoint Diagnostics Ltd.** VentriPoint creates diagnostic tools to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is based upon technology licensed exclusively by VentriPoint from the University of Washington. The VMS is being adapted for a variety of heart-related diseases, with congenital heart disease representing the first application and pulmonary



hypertension, cardiovascular disease and heart failure in process as the intended disease applications to follow.

For further information, please contact:

**VentriPoint Diagnostics**

Ed Garth, Chief Financial Officer  
Telephone: (206) 283-0221, ext. 402  
Facsimile: (206) 283-2309

**CHF Investor Relations**

Christopher Haldane, Account Manager  
Telephone: (416) 868-1079 ext.237  
Facsimile: (416) 868-6198

To receive press release, please email [chris@chfir.com](mailto:chris@chfir.com) and mention VentriPoint in the Subject line

**Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release**

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.